Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
23,800
Grifols SA News & Analysis
stocks
6 undervalued stocks with low beta
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.50 | 7.00 | 0.08% |
| CAC 40 | 8,243.47 | 6.04 | 0.07% |
| DAX 40 | 25,127.46 | 5.20 | 0.02% |
| Dow JONES (US) | 49,266.11 | 270.03 | 0.55% |
| FTSE 100 | 10,021.34 | 26.87 | -0.27% |
| HKSE | 26,149.31 | 561.14 | -2.10% |
| NASDAQ | 23,480.02 | 67.16 | -0.29% |
| Nikkei 225 | 51,117.26 | 1,400.82 | -2.67% |
| NZX 50 Index | 13,717.80 | 0.94 | 0.01% |
| S&P 500 | 6,921.46 | 0.53 | 0.01% |
| S&P/ASX 200 | 8,720.80 | 2.70 | -0.03% |
| SSE Composite Index | 4,082.98 | 2.79 | -0.07% |